CONNECT WITH US
HealthTech

HealthTech

Mount Sinai Scientists Launch Human Tissue Organoids into Space: SpaceX CRS-35 Investigates Neurological and Cardiovascular Aging

HIT Consultant logo

Published on

Add as a preferred source on Google
Mount Sinai Scientists Launch Human Tissue Organoids into Space: SpaceX CRS-35 Investigates Neurological and Cardiovascular Aging

Mount Sinai Health System researchers launched bioengineered human brain and cardiovascular tissue models into orbit aboard the SpaceX CRS-35 Commercial Resupply Services mission to the International Space Station (ISS).

Developed across Mount Sinai’s Departments of Stem Cell Biology and Regenerative Medicine, Neuroscience, and Surgery, alongside the Cardiovascular Research Institute, the dual investigations pair patient-derived stem cell organoids and microfluidic “organ-on-a-chip” systems with automated space biology hardware engineered by Space Tango in collaboration with NASA.

Leverages the microgravity and elevated radiation environment of low Earth orbit (LEO) as an accelerated biological model to study the cellular mechanics of human aging, neurodegeneration, and cardiovascular decline.

The mission deploys two distinct human tissue platforms into low Earth orbit to assess neurological signaling, vascular dynamics, and cellular stress in real time:

The miBrain Platform (Neural Aging & Genetic Susceptibility): Cellular Composition: Derived from human induced pluripotent stem cells (iPSCs), the miBrain model reconstructs human brain tissue architecture by incorporating all major cerebral cell lineages—including neurons, astrocytes, microglia (immune cells), and functional microvasculature.

Orbital Science Objectives: Led by Joel W. Blanchard, PhD, the project evaluates how microgravity and elevated space radiation alter neural cellular communication, blood-brain barrier permeability, and neuroinflammatory injury markers.

Terrestrial Disease Modeling: Crucially, the mission tests how high-risk neurodegenerative genetic variants—specifically the APOE4 allele, the strongest genetic risk factor for late-onset Alzheimer’s disease—influence cellular aging kinetics and susceptibility to environmental stressors, comparing orbital degradation rates against baseline Earth controls.

The µCVchip Platform (Functional Cardiovascular Organoids): Automated Microfluidic Architecture: Co-led by Kevin D.



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.